Evgen Pharma PLC Manchester Breast Centre collaboration expanded
07 Marzo 2022 - 1:01AM
RNS Non-Regulatory
TIDMEVG
Evgen Pharma PLC
07 March 2022
Evgen Pharma plc
("Evgen" or the "Company")
Expansion of collaboration with the Manchester Breast Centre
Evgen Pharma plc (AIM: EVG), a clinical stage drug development
company, announces an expansion of its collaboration with the
Manchester Breast Centre at the University of Manchester's School
of Medical Sciences, in a continued drive to establish the optimum
clinical positioning for lead asset SFX-01 in metastatic breast
cancer ("mBC").
Since the STEM open-label Phase II trial of SFX-01 in mBC trial
concluded, CDK4/6 inhibitors have become standard of care as the
first line mBC treatment for the large group of patients who are
estrogen receptor positive (ER+ve), human epidermal growth factor
receptor 2 negative ("HER-2 negative"). These drugs provide an
extended period of progression-free survival, but invariably
patients' tumours become resistant to them. Options for such
patients are limited, especially since drugs used in this setting
are poorly tolerated.
Accordingly, Evgen is expanding its work with Professor Rob
Clarke at the Manchester Breast Centre with in vitro preclinical
work to assess the impact of SFX-01 in CDK4/6 resistance models. An
increasing body of in vitro data from these models shows that
SFX-01 may suppress tumour growth and metastasis in patients who
have become resistant to CDK4/6 inhibitors. In particular, SFX-01
reduces the viability and mammosphere colony formation of
palbociclib-resistant tumour cell lines in vitro.
In addition, the extended collaboration will include in vivo
models to provide the optimum support for clinical trial design
and/or licensing in patients with HER-2 negative, ER+ve breast
cancer, where CDK4/6 inhibitors such as palbociclib are showing
weakening effectiveness. Evgen anticipates data from both in vitro
and in vivo work later in the year.
Palbociclib, marketed by Pfizer, is the leading CDK4/6
inhibitor; in 2019 it had sales of circa $5bn.
Dr Huw Jones, Evgen CEO, commented: "We are delighted to expand
this collaboration with Rob and Dr Bruno Simões and the team, and
we remain passionate about optimising the use of SFX-01 to improve
patient outcomes. Breast cancer remains our top priority alongside
brain cancer, and we hope ultimately to provide an effective
treatment for these patients as the current options for treatment
become more limited."
Prof Rob Clarke, Professor of Breast Biology at the University
of Manchester, added: "We look forward to working closely with the
Evgen Pharma team to advance our work on SFX-01 in breast cancer,
and to demonstrate its effectiveness in patients who are resistant
to the current standard of care treatments."
The Company's previous open-label STEM trial in patients who had
not received CDK4/6 inhibitors demonstrated:
-- Evidence of anti-cancer activity via objective responses (tumour shrinkage)
-- 24% of patients showed a durable clinical benefit for at
least six months, despite the late stage of disease and patients'
established resistance to hormone therapy. Of these, five patients
were still receiving SFX-01 at 12 months and one patient remained
on SFX-01treatment for 18 months
-- A mild and favourable side effect profile for an anti-cancer drug.
Enquiries:
Evgen Pharma plc www.evgen.com via Walbrook
Dr Huw Jones, CEO
Richard Moulson, CFO
finnCap www.finncap.com +44 (0)20 7220 0500
Geoff Nash / Teddy Whiley (Corporate
Finance)
Alice Lane / Nigel Birks (ECM)
Walbrook PR +44 (0)20 7933 87870 or evgen@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7876
Paul McManus / Anna Dunphy 741 001
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company
developing sulforaphane based medicines for the treatment of
multiple diseases. The Company's core technology is Sulforadex(R),
a method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane. The lead product, SFX-01, is a patented composition
of synthetic sulforaphane and alpha-cyclodextrin.
Clinical data from the Company's open-label Phase II STEM trial
has shown that SFX-01 can halt the growth of progressing tumours in
patients with oestrogen-positive (ER+) metastatic breast cancer,
and in some cases significantly shrink the tumour, whilst causing
very few side effects.
The Company commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire, and its registered
office is at the Liverpool Science Park, Liverpool. It joined the
AIM market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRASSUFWDEESEED
(END) Dow Jones Newswires
March 07, 2022 02:01 ET (07:01 GMT)
Evgen Pharma (LSE:EVG)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Evgen Pharma (LSE:EVG)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024